Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
Servier and n-Lorem Foundation have announced a multi-target research collaboration aimed at advancing antisense oligonucleotide (ASO) therapeutic approaches for rare neurodevelopmental disorders. This partnership is expected to enhance the number of patients n-Lorem can treat, addressing significant unmet medical needs.
As part of the collaboration, n-Lorem's research teams will utilize their ASO technology platform to engineer preclinical candidates, which Servier will further develop into clinical applications. ASOs are designed to target disease-causing RNA, potentially enabling personalized treatment approaches for genetic disorders and addressing the root causes of these diseases.
The partnership aligns with Servier's commitment to focusing on rare neurological diseases. Through this collaboration, the two organizations aim to expand the availability of precision genetic medicine for patients affected by rare neurological disorders, many of whom currently lack approved treatment options. This initiative also contributes to Servier's 2030 goal of developing innovative treatments in areas of high unmet medical need, including refractory epilepsy and movement disorders.
"We are proud to partner with n-Lorem, sharing the same commitment to advancing personalized ASOs and bringing meaningful therapies to people living with rare genetic neurological disorders who have few, if any, treatment options available today," said Nitza Thomasson, Global Head of R&D Neurology at Servier. "This partnership builds on a shared belief in open, multidisciplinary collaboration grounded in strong science to accelerate research and deliver new therapies for patients."
Stanley T. Crooke, Founder, Chairman and CEO of n-Lorem, added, "We welcome Servier to our growing list of supporters and partners and look forward to contributing to Servier's commitment to patients with rare neurological disorders and to advancing ASO technology. This is truly a win-win for patients with rare diseases."